Literature DB >> 18438125

Gene silencing of CD47 and antibody ligation of thrombospondin-1 enhance ischemic tissue survival in a porcine model: implications for human disease.

Jeff S Isenberg1, Martin J Romeo, Justin B Maxhimer, Jeremy Smedley, William A Frazier, David D Roberts.   

Abstract

BACKGROUND: Insufficient tissue perfusion underlies many acute and chronic diseases. Tissue perfusion in turn requires adequate blood flow, determined in large part by the relative state of relaxation or constriction of arterial vessels. Nitric oxide (NO) produced by vascular cells modulates blood flow and tissue perfusion by relaxing and dilating arteries. Recently, we reported that the secreted protein thrombospondin-1 (TSP1), through its cell surface receptor CD47, limits the ability of NO to relax and dilate blood vessels and thus decreases tissue perfusion. In the present study, we tested the hypothesis that blocking TSP1-CD47 signaling increases ischemic tissue survival in random cutaneous porcine flaps.
METHODS: Random cutaneous flaps 2 x 10 cm2 were raised in white hairless Yucatan miniature pigs and were treated with a monoclonal antibody to TSP1, an antisense morpholino oligonucleotide to CD47 or control agents and tissue survival assessed. Primary vascular smooth muscle cell cultured from Yucatan pigs were also treated with the same agents +/- and an NO donor (DEA/NO) and cGMP quantified.
RESULTS: Antibody blockade of TSP1 or morpholino suppression of CD47 dramatically enhanced survival of random tissue flaps. These responses correlated with increased blood vessel patency and tissue blood flow on vessel injection studies. NO-stimulated cGMP flux in Yucatan vascular smooth muscle cell was abrogated after antibody or morpholino treatment.
CONCLUSION: Antibody ligation of TSP1 or antisense morpholino knock down of CD47 greatly increased tissue survival to ischemia. Given the similarity between porcine and human soft tissues these results suggest significant therapeutic potential for people.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18438125      PMCID: PMC2430143          DOI: 10.1097/SLA.0b013e31816c4006

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  49 in total

Review 1.  The ageing of the blood supply and the lymphatic drainage of the skin.

Authors:  Terence Ryan
Journal:  Micron       Date:  2004       Impact factor: 2.251

Review 2.  Nitric oxide in wound-healing.

Authors:  Jeff S Isenberg; Lisa A Ridnour; Michael Graham Espey; David A Wink; David D Roberts
Journal:  Microsurgery       Date:  2005       Impact factor: 2.425

3.  Thrombospondin 1 and its specific cysteine-serine-valine-threonine-cysteine-clycine receptor in fetal wounds.

Authors:  J J Roth; J J Sung; M S Granick; M P Solomon; M T Longaker; V L Rothman; R F Nicosia; G P Tuszynski
Journal:  Ann Plast Surg       Date:  1999-05       Impact factor: 1.539

Review 4.  Medical treatment of peripheral arterial disease.

Authors:  Graeme J Hankey; Paul E Norman; John W Eikelboom
Journal:  JAMA       Date:  2006-02-01       Impact factor: 56.272

5.  Nitric oxide-induced decrease in calcium sensitivity of resistance arteries is attributable to activation of the myosin light chain phosphatase and antagonized by the RhoA/Rho kinase pathway.

Authors:  Steffen-Sebastian Bolz; Lukas Vogel; Daniel Sollinger; Roland Derwand; Cor de Wit; Gervaise Loirand; Ulrich Pohl
Journal:  Circulation       Date:  2003-06-09       Impact factor: 29.690

6.  Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation.

Authors:  Jeff S Isenberg; Fuminori Hyodo; Ken-Ichiro Matsumoto; Martin J Romeo; Mones Abu-Asab; Maria Tsokos; Periannan Kuppusamy; David A Wink; Murali C Krishna; David D Roberts
Journal:  Blood       Date:  2006-11-02       Impact factor: 22.113

7.  Accumulation of thrombospondin-1 in post-operative capsular fibrosis and its down-regulation in lens cells during lens fiber formation.

Authors:  Shizuya Saika; Takeshi Miyamoto; Iku Ishida; Walid K Barbour; Yoshitaka Ohnishi; Akira Ooshima
Journal:  Exp Eye Res       Date:  2004-08       Impact factor: 3.467

8.  Hypoxia increases thrombospondin-1 transcript and protein in cultured endothelial cells.

Authors:  M W Phelan; L W Forman; S P Perrine; D V Faller
Journal:  J Lab Clin Med       Date:  1998-12

9.  Blocking thrombospondin-1/CD47 signaling alleviates deleterious effects of aging on tissue responses to ischemia.

Authors:  Jeff S Isenberg; Fuminori Hyodo; Loretta K Pappan; Mones Abu-Asab; Maria Tsokos; Murali C Krishna; William A Frazier; David D Roberts
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-10-04       Impact factor: 8.311

10.  Nitric oxide synthase inhibitors improve skin flap survival in the rat.

Authors:  L K Knox; A G Stewart; P G Hayward; W A Morrison
Journal:  Microsurgery       Date:  1994       Impact factor: 2.425

View more
  39 in total

1.  Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47.

Authors:  Sukhbir Kaur; Gema Martin-Manso; Michael L Pendrak; Susan H Garfield; Jeff S Isenberg; David D Roberts
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

Review 2.  The matricellular protein thrombospondin-1 globally regulates cardiovascular function and responses to stress via CD47.

Authors:  David D Roberts; Thomas W Miller; Natasha M Rogers; Mingyi Yao; Jeffrey S Isenberg
Journal:  Matrix Biol       Date:  2012-01-14       Impact factor: 11.583

Review 3.  CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest.

Authors:  E Sick; A Jeanne; C Schneider; S Dedieu; K Takeda; L Martiny
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

Review 4.  The role of CD47 in pathogenesis and treatment of renal ischemia reperfusion injury.

Authors:  Jeffrey S Isenberg; David D Roberts
Journal:  Pediatr Nephrol       Date:  2018-11-03       Impact factor: 3.714

5.  Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP.

Authors:  Mingyi Yao; David D Roberts; Jeff S Isenberg
Journal:  Pharmacol Res       Date:  2010-10-29       Impact factor: 7.658

Review 6.  Molecular regulation of tumor angiogenesis and perfusion via redox signaling.

Authors:  Thomas W Miller; Jeff S Isenberg; David D Roberts
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

Review 7.  Matricellular protein thrombospondin-1 in pulmonary hypertension: multiple pathways to disease.

Authors:  Natasha M Rogers; Kedar Ghimire; Maria J Calzada; Jeffrey S Isenberg
Journal:  Cardiovasc Res       Date:  2017-07-01       Impact factor: 10.787

Review 8.  Nitric oxide: what's new to NO?

Authors:  Kedar Ghimire; Helene M Altmann; Adam C Straub; Jeffrey S Isenberg
Journal:  Am J Physiol Cell Physiol       Date:  2016-12-14       Impact factor: 4.249

Review 9.  Divergent modulation of normal and neoplastic stem cells by thrombospondin-1 and CD47 signaling.

Authors:  Sukhbir Kaur; David D Roberts
Journal:  Int J Biochem Cell Biol       Date:  2016-05-06       Impact factor: 5.085

10.  Thrombospondins function as regulators of angiogenesis.

Authors:  Paul Bornstein
Journal:  J Cell Commun Signal       Date:  2009-10-02       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.